Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-3.A1 + NA17.A2
- Development stage
- Unknown
- Lead developer
- Cliniques universitaires Saint-Luc
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intradermal
01
Overview
MAGE-3.A1 + NA17.A2 is a combination peptide-based therapeutic cancer vaccine developed by Cliniques universitaires Saint-Luc and the Université Catholique de Louvain. It consists of two synthetic peptides: MAGE-3.A1 (sequence: EVDPIGHLY), a cancer-testis antigen restricted to HLA-A1, and NA17.A2 (sequence: VLPDVFIRC), an antigen derived from N-acetylglucosaminyltransferase V restricted to HLA-A*0201. The vaccine is designed to stimulate a cytolytic T lymphocyte (CTL) response against melanoma cells expressing these specific tumor-associated antigens (TAAs). In clinical research, this vaccine has been evaluated in combination with GM-CT-01 (a galectin-3 inhibitor) to overcome tumor-infiltrating lymphocyte (TIL) anergy in patients with advanced metastatic melanoma.
- Other names
- MAGE-3.A1 + NA17.A2 peptide vaccineMAGE-3.A1 peptideMAGE3.A1 peptideMAGE 3.A1 peptideNA17.A2 peptideNA-17.A2 peptideNA 17.A2 peptide
02
Targets
MAGEA3 (Melanoma-associated antigen 3)NA17-A2 pMHC-I (NA17-A peptide-HLA-A*02:01 complex)
Beyond the preview
Go deeper on MAGE-3.A1 + NA17.A2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-3.A1 + NA17.A2.